After many setbacks, the potential for CETP inhibition to significantly improve cholesterol levels and target attainment has been shown with obicetrapib in the ROSE trial.
New post-hoc data accepted as late breaking abstracts at the 90th European Atherosclerosis Society (EAS) Congress and 2022 National Lipid Association (NLA) Scientific Sessions NewAmsterdam Pharma
Gamechanging heart disease drug approved for use in England | Drugs theguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theguardian.com Daily Mail and Mail on Sunday newspapers.
Real-world PCSK9i Data in FH Reveal Conundrum of Reimbursement medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Scientists are working on a way to ‘silence’ a genetic flaw that increases the risk of heart attacks.
The defect raises the amount of a fatty protein called Lipoprotein (a), which is found in potentially dangerous levels in 20 per cent of the population.
It causes blood to clot too easily and cannot be controlled by lifestyle changes.
Researchers are trying to develop new ways of bringing levels down using so-called ‘RNA inhibitors’.
Scientists are working on a way to ‘silence’ a genetic flaw that increases the risk of heart attacks
The aim is to develop a long-lasting injectable drug given only a couple of times a year.